Deconvoluting the cellular black box of cell therapies for osteoarthritis: A mandate for protocol standardization.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Autologous cell therapies for knee osteoarthritis, including bone marrow aspirate concentrate (BMAC) and stromal vascular fraction (SVF), have advanced clinically despite an incomplete understanding of their mechanisms. Chatterjee et al. apply single-cell transcriptomics to multicenter trial of stem cell therapy for osteoarthritis (MILES) trial samples, revealing that site-to-site technical variability in BMAC composition overwhelms biological signals associated with treatment response. This finding mandates urgent standardization of harvest protocols before personalized genomic profiling can be meaningfully implemented. While responder/non-responder differences were subtle, pathway enrichment analyses and cell-cell communication inferences suggest that therapeutic outcomes may depend more on dynamic post-injection interactions than on baseline cellular states. The study establishes a foundational framework for evidence-based quality control in cellular orthopedics.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.